GD2 CAR T-cell treatment for pediatric brain tumors
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a special immune-cell therapy (GD2 CAR T cells) made for pediatric brain tumor patients. It uses a planned treatment plan and monitoring to see if the therapy is safe and can work against the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You need a recent MRI scan within 14 days before starting treatment
- Age must be 6 months to 30 years
- Your brain tumor must be measurable on MRI in at least two areas
- You must be well enough to take part (Karnofsky/Lansky score at least 60)
- You must have recovered from prior radiation/chemo side effects to mild levels (grade 1–2) or be clinically stable
- Doctors must place a small drain device in the brain area and a microdialysis probe for study monitoring
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests CAR T cells designed to target a marker called GD2 on brain tumors. It aims to see if the treatment is safe and whether it can shrink or control these tumors in children and young adults.
This trial tests a new immune cell therapy (CAR T-cells) that targets a protein called CD70 found on some brain tumor cells. It is for children and young adults with newly diagnosed or recurrent high-grade glioma, including DIPG.
This trial tests a new CAR T cell therapy (BCB-276) for children and young adults with a type of brain tumor called DIPG. The therapy uses your own immune cells that are specially trained to attack the cancer.
This Phase 1 trial tests a personalized immune-cell treatment (CAR T) delivered directly in the brain-area space using a catheter. It may help children and young adults with hard-to-treat (recurrent or refractory) diffuse midline brain tumors like DIPG/DMG when standard options aren’t working.
This trial tests a new type of immunotherapy called B7H3 IL-7Ra CAR T-cells for children with DIPG, a tough-to-treat brain tumor. The treatment is given directly into the fluid around the brain using a special catheter, and the goal is to see if it's safe and if it can help fight the tumor.
This trial tests a special immune cell treatment (GD2-CAR T cells) for children and teens with neuroblastoma that has come back or not responded to standard therapy. It aims to see if these engineered cells can find and attack the cancer.
Hear when a new Medulloblastoma, Childhood trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.